{ "slug": "inflammation-depression", "case_path": "hsef_v53_remaining_priority_06_10_2026-10-09\\inflammation-depression", "round": 2, "group": 1, "review_date": "2026-10-14", "adversarial_reviewer": "Claude Opus 5.5 (Anthropic)", "authoring_model_of_record": "Sol 6.1", "authoring_model_as_declared_in_package": "Codex; HSEF v5.3", "status": "Approved as revised", "level_before": "Γ", "level_after": "Γ", "descriptor_after": "Mechanistically plausible, partial system support", "confidence_before": "Moderate", "confidence_after": "Moderate", "role_before": "reinforcing / stabilizing factor", "role_after": "reinforcing / stabilizing factor", "subclaims_before": { "SC1": "Β", "SC2": "Ε", "SC3": "Γ" }, "subclaims_after": { "SC1": "Β", "SC2": "Ε", "SC3": "Γ" }, "aggregation_rule": "primary-subclaim (SC3)", "aggregation_alternatives": { "weakest_link": "Β", "primary_subclaim": "Γ", "scope_matched": "Γ" }, "msd_before": { "momentum": "Decisive work underway", "stability": "Uncertain", "divergence": "Contested" }, "msd_after": { "momentum": "Decisive work underway", "stability": "Uncertain", "divergence": "Contested" }, "sources_total_before": 56, "sources_total_after": 56, "claims_total": 60, "pmids_checked": 62, "pmids_reference_list": 56, "pmids_prose_or_scorecard_only": 6, "pmids_failed": 0, "retractions_or_eocs_found": 0, "claims_spot_checked": 12, "claims_spot_check_failures": 1, "validator": { "tool": "framework/hsef-hypothesis-review-v5/tools/validate_review.py", "before": "PASS - 0 fail, 0 warn, 31 pass", "after": "PASS - 0 fail, 0 warn, 31 pass", "output_file": "validator.txt" }, "findings_by_severity": { "critical": 0, "major": 2, "minor": 2, "editorial": 1 }, "findings": [ { "id": "D-1", "severity": "Minor", "category": "rendering defect / internal inconsistency", "location": "document-wide", "original": "74 occurrences of PMID fused to its digits", "corrected": "PMID ", "evidence": "The whitespace-loss defect class named in the round-2 brief. The reference list already used the spaced form 69 times in the same document.", "artifacts_changed": [ "inflammation-depression.review.md" ] }, { "id": "D-2", "severity": "Editorial", "category": "rendering defect", "location": "Momentum paragraph, 'Final score, causal direction and M/S/D'", "original": "DOI10.1016/j.bbih.2024.100871", "corrected": "DOI 10.1016/j.bbih.2024.100871", "evidence": "Same defect class, missing space after the label. The identifier is correct and resolves to the INSTA-MD protocol (PMID 39350954).", "artifacts_changed": [ "inflammation-depression.review.md" ], "note": "The same fused string remains in the scorecard's extended_scoring_MSD momentum artifact and justification fields." }, { "id": "D-3", "severity": "Minor", "category": "balance / incomplete reporting of a primary result", "location": "Evidence and causal interpretation - immune-challenge paragraph", "original": "The high-CRP MDD challenge measures anhedonia at 1.5 hours, has a nonsignificant overall three-way primary interaction and does not measure MADRS at the peak; the later MADRS group effect reflects improvement.", "corrected": "The high-CRP MDD challenge measures anhedonia at 1.5 hours: its prespecified primary contrast, the baseline-to-1.5-hour SHAPS change in the high-CRP versus low-CRP endotoxin groups, was significant, while the overall three-way primary interaction was not. It does not measure MADRS at the peak, and the later MADRS group effect reflects improvement.", "evidence": "PMID 40264292 states that the primary outcome measure was the SHAPS and the primary contrast of interest was the baseline-to-1.5-hour change in the high-CRP versus low-CRP LPS groups, and reports that contrast as significant. The original prose named only the null limb of the primary analysis, so a prose-only reader could conclude the primary analysis failed.", "severity_rationale": "A balance gap rather than a misstatement: the evidence card for this source already records 'Baseline-high-CRP MDD participants have greater acute anhedonia under inflammatory challenge', and the rival-model entry credits the trial with separating genuine immune-triggered acute anhedonia from a purely shared-cause account. The correction makes the prose match the card.", "level_impact": "None. The review already treats the challenge as acute-susceptibility evidence that cannot establish sustained-MDD initiation, which is what holds SC3 at Gamma.", "artifacts_changed": [ "inflammation-depression.review.md" ] }, { "id": "D-4", "severity": "Major", "category": "false provenance claim", "location": "Registered claim and scope - Selection sentence", "original": "Registered claim assessed against original sources; existing HIV draft consulted after a source-based checkpoint. This is not independent blinded calibration.", "corrected": "Registered claim assessed against original sources. This is not independent blinded calibration.", "evidence": "No HIV draft belongs to this case's provenance. The clause is batch boilerplate present identically in all five case files of hsef_v53_remaining_priority_06_10_2026-10-09 and accurate only for hiv-aids.", "lead_flagged": true, "precedent": "Another group applied the same correction to dopamine-schizophrenia.", "artifacts_changed": [ "inflammation-depression.review.md" ] }, { "id": "D-5", "severity": "Major", "category": "confidence band justified by reviewer access depth", "location": "inflammation-depression.scorecard.json, final_score.confidence_rationale", "original": "56 primary reports with 5 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness.", "corrected": "Moderate reflects evidence density and reproducibility, not correctness and not this reviewer's access depth. The association and Mendelian-randomization literature is large but heterogeneous and partly discordant, while the trials bearing on the registered claim are few, use pleiotropic agents and include only one prospectively stratified test. Access depth is recorded separately in the provenance header and is not a basis for the band.", "evidence": "The framework states confidence reflects evidence density and reproducibility, and that access depth is a statement about the reviewer, not the source.", "band_changed": false, "band_argued_both_ways": "Moderate stands: the trials bearing on the registered claim are few, use pleiotropic agents and include only one prospectively stratified test, so the High text's extensive-replication requirement is not met.", "lead_flagged": true, "artifacts_changed": [ "inflammation-depression.scorecard.json" ] } ], "rejected_findings": [ { "id": "R-1", "checked": "References printing a year one off the PubMed publication-date year", "disposition": "Rejected per the round-2 print-versus-e-pub convention." }, { "id": "R-2", "checked": "Headline Gamma drawn from a subclaim set whose highest member is an Epsilon (SC2)", "disposition": "Rejected - this is the brief's warned pattern, handled correctly. The pre-registered rule is primary-subclaim and the primary subclaim SC3 is the registered claim verbatim; SC2's Epsilon is explicitly scope-restricted to prolonged interferon treatment in a defined medical setting and so cannot set the broadly scoped headline. Scope-matched returns Gamma for the same reason, weakest-link returns Beta, and all three are reported." }, { "id": "R-3", "checked": "Momentum 'Decisive work underway'", "disposition": "Rejected. Unusually specific artifact: INSTA-MD named with NCT05644301, protocol PMID 39350954 (verified: hsCRP>=3 stratification, 240 planned patients, celecoxib/minocycline), the date the registry was read, the fact that the registry's last verification predates that read, and an explicit statement that completion and results are not asserted. AT A GLANCE adds that INSTA-MD addresses only part of the deciding design." }, { "id": "R-4", "checked": "Tally of 4 positive qualifying study units against a printed decisive-perturbation inventory of 7 items", "disposition": "Rejected - the inventory lists perturbations of both signs; the tally counts only positive qualifying units, and the review states that null and negative contrasts are discriminators, not positive threshold crossings. Scorecard claimed and post-audit tallies agree at 4." }, { "id": "R-5", "checked": "Role 'reinforcing / stabilizing factor' rather than 'primary driver'", "disposition": "Rejected - the derivation runs the framework's ordered procedure and stops at step 5, naming which primary-driver limbs are missing at the registered scope." }, { "id": "R-6", "checked": "Errata (PMID 32807844, 34785785, 41152245) and two preprints (PMID 38699368, 39149475) of reference 11 absent from the numbered list", "disposition": "Rejected - correct handling. Corrections attach to the parent row and never take a numbered row; the preprints are the same study as reference 11, a supersession rather than a second source. Counting any of them would inflate sources_total." }, { "id": "R-7", "checked": "Reference-builder collective-author defect (leading comma, dropped consortium author)", "disposition": "Rejected, checked and not present. All 56 references carry a named individual first author." }, { "id": "R-8", "checked": "Fused word pairs of the kind present elsewhere in this release", "disposition": "Rejected for this review, checked and not present. Apart from the PMID and DOI label fusions corrected above, every alphabetic token of 13+ characters in the reader-facing sections and 15+ in the apparatus is a real English or journal-title word." }, { "id": "R-9", "checked": "Renderer bug: 'Best-supported rival' printing models_evaluated[0], often the nominal", "disposition": "Rejected - not present. models_evaluated[0] is 'Context-specific immune effects' (rank 1, is_nominal false); the nominal inflammatory-MDD-subtype model is index 3, rank 4. The prose names the rank-1 non-nominal model." } ], "residual_limitations": [ "51 of 56 records are at bounded abstract and status depth. Two weight-bearing numbers could not be reached at abstract depth and rest on the review's own selected-body passages: the 'six high-CRP treated participants' in the CRP-selected minocycline trial's exploratory stratum (PMID 33504955) and the nonsignificant overall three-way interaction in the high-CRP endotoxin challenge (PMID 40264292). Both are consistent with their abstracts and the review names the body sections it read; neither is flagged as an error.", "SC2's Epsilon rests on interferon-treatment cohorts in which immune exposure is generally not randomized, which the review states. The letter therefore depends on treating a therapeutic perturbation in a defined medical context as field-valid - rubric 05 permits it, but it is weaker than a randomized immune-initiation test.", "The grade turns on a single prospectively stratified null (PREDDICT, one drug, n=119). The review says so and declines to call the subtype refuted; Gamma should not be read as a refutation." ], "scorecard_changed": true, "scorecard_change_reason": "One line only: final_score.confidence_rationale (finding D-5). No level, band, count or role moved.", "package_level_propagation": { "strings_to_replace": [ { "what": "inflammation-depression.review.md sha256 in this case folder's SHA256.txt and in any package MANIFEST.json / BATCH_COMPLETION.json entry carrying it", "old": "87ea8f5285c17043e69b8952173137b23271985aa88238e2d4f3bbdb69e4dda4", "new": "13f128d497aeebd050d4e5176849fd44952cd487b1b646a2f29264ead7f91a52" } ], "batch_wide_action": "The PMID fusion is present in all five case files of hsef_v53_remaining_priority_06_10_2026-10-09 (dopamine-schizophrenia 73, hiv-aids 52, inflammation-depression 74, lipid-heart-diet 55, telomere-shortening 59) alongside the spaced form in the same documents, and in the scorecard JSONs. Recommend a regeneration pass over the batch.", "note": "No headline string, letter, confidence, count or title changed, so OVERVIEW.md-class values are not stale." }, "changed_file_hashes": { "inflammation-depression.review.md": { "sha256": "0c7c865d65e0ac14590dc80f518db78a7e7439c529effaa2666924603d6f2ac9", "bytes": 98650, "previous_sha256": "87ea8f5285c17043e69b8952173137b23271985aa88238e2d4f3bbdb69e4dda4" }, "validator.txt": { "sha256": "d4fb23dfd84f18244f7a18b288d3ec4c92aea5eee2d3b5feb0010c73a64913da", "bytes": 2411, "new_file": true }, "ADVERSARIAL_REVIEW.md": { "sha256": "2a781850578719cc2d0e00464a96346aba49b613a7de2505e2aad00bced37467", "bytes": 8759, "new_file": true }, "inflammation-depression.scorecard.json": { "sha256": "52286444f9fe402328ef193d698e6569ffcce0ecfdc560aae4ce449b0ceb161b", "bytes": 275110, "previous_sha256": "fdb89faea61d9604c79bc5a3cf64bf1a2065db7d3910ef3e37437244ef077f7a", "change_detail": "One line only: final_score.confidence_rationale (finding D-5). No level, band, count or role moved." } }, "propagate_to": [], "divergent_copies": [], "consensus_questions": [ "In adults with major depressive disorder stratified PROSPECTIVELY by a pre-fixed baseline inflammatory marker threshold, does anti-inflammatory or immune-targeted augmentation produce a significant treatment-by-stratum interaction on depressive symptoms?", "Does Mendelian randomization support a causal effect of IL-6 signalling, as distinct from CRP, on major depression?" ], "lead_flagged_artifact_checks": { "false_approval_boilerplate": "not applicable", "confidence_from_access_depth": "present; rationale corrected, band unchanged (D-5)", "models_evaluated_0_renderer_bug": "absent (R-9)", "reviewer_notes_contradiction": "not applicable", "false_hiv_draft_clause": "present; corrected (D-4)", "review_metadata_reviewer_left_unedited": true }, "line_endings_note": "CRLF preserved on every edited file, so each diff against sol61-original is confined to the corrected content.", "lead_policy_2026_10_14": { "confidence_two_step_test": { "step1_strike_access_depth": "applied; access-depth clause removed from the rationale (finding D-5)", "step2_rederive_band": "Moderate stands", "surviving_valid_determinants": [ "association and Mendelian-randomization literature large but heterogeneous and partly discordant: IL6R genotype raises circulating IL-6 while lowering downstream CRP, and several CRP analyses are null against positive observational associations", "trials bearing on the registered claim are few and use pleiotropic agents (infliximab, minocycline, celecoxib, EPA) rather than selective pathway blockade", "only one prospectively stratified test exists (PREDDICT, one drug, n=119)", "CRP is a reporter rather than an endogenous tissue readout, a determinant the policy names as valid" ], "band_before": "Moderate", "band_after": "Moderate", "band_changed": false }, "momentum_stricter_rule": { "value": "Decisive work underway", "result": "holds", "basis": "INSTA-MD (NCT05644301) is a trial actually being run: the registry read on 11 October 2026 lists it RECRUITING, the investigator page actively invites participants, and completion and results are not asserted, while the review honestly notes the registry's last verification predates the read. It is the prospectively stratified marker test that would cross SC3's threshold. The protocol publication (PMID 39350954) is cited to identify the trial, not credited as a completed result.", "completed_work_counted_as_momentum": false }, "policy_as_stated_by_lead": "Confidence: strike access depth as a determinant everywhere, then re-derive; raise the band only if access depth was the only thing holding it down and the cited evidence meets the High text. Documented evidence-quality or reproducibility concerns are valid determinants and the band stands. Momentum: 'Decisive work underway' requires work actually being run that could cross the next threshold; a completed publication or trial never satisfies it." } }